Humulin I Kwikpen (Isophane) (Insulin Human (Rdna))

Humulin I Kwikpen is indicated for the treatment of diabetes mellitus where basal insulin support is required to maintain target blood glucose levels.

• Adjunct therapy in type 1 diabetes to provide intermediate‑acting insulin coverage between meals.
• Supplemental basal insulin in type 2 diabetes when oral agents no longer achieve glycemic goals.
• Part of an individualized insulin regimen combined with rapid‑acting insulin for intensive control.
• Used in patients transitioning from twice‑daily NPH injections to a pen‑based delivery system.
• Employed when consistent dosing and ease of administration are clinically advantageous.

• Insulin human (isophane) is a recombinant form of human insulin that forms microprecipitates after subcutaneous injection, creating a depot that releases insulin slowly. The molecule binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, increasing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering plasma glucose concentrations over a 12‑ to 18‑hour period.

The most frequently reported adverse reactions to Humulin I Kwikpen are related to its pharmacologic action and injection site.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Redness, swelling, or itching at the injection site.
• Lipodystrophy presenting as localized thickening or loss of subcutaneous fat.
• Weight gain associated with improved glycemic control.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms such as confusion or loss of consciousness.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or fluid retention leading to peripheral swelling.
• Hypersensitivity dermatitis extending beyond the injection area.

When prescribing Humulin I Kwikpen, clinicians should evaluate patient-specific factors and monitor for conditions that may alter insulin requirements.

• Assess renal and hepatic function, as impairment can prolong insulin action and increase hypoglycemia risk.
• Adjust dose during periods of illness, surgery, or significant changes in physical activity.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid use in patients with known hypersensitivity to human insulin or any pen components.
• Consider pregnancy status; insulin requirements may change and close monitoring is essential.
• Store the pen at controlled room temperature and discard after the indicated in‑use period.

Humulin I Kwikpen may interact with other medications that affect glucose metabolism or insulin absorption.

Avoid

• Concurrent use of other insulin products without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, potentially delaying treatment.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase insulin secretion.
• Corticosteroids, which may raise blood glucose and require higher insulin doses.
• Thiazide diuretics, which can reduce potassium levels and affect insulin sensitivity.
• Alcohol consumption, especially in excess, as it can cause delayed hypoglycemia.